Digestive Endoscopy Unit, University Campus Bio-Medico, Rome, Italy.
Endoscopy Division, Yokohama City University Medical Center, Yokohama, Japan.
Dig Liver Dis. 2021 Jul;53(7):889-894. doi: 10.1016/j.dld.2021.03.005. Epub 2021 Mar 21.
Endoscopic submucosal dissection (ESD) is the treatment of choice for colorectal superficial neoplasia, but certain anatomical locations are challenging even for skilled endoscopists. Ileocecal valve (ICV) is considered a technically challenging site for ESD.
Aim of this study was to analyze efficacy and safety of Endoscopic Submucosal Dissection in the treatment of colorectal neoplasia involving the ileocecal valve (ICV) DESIGN: Retrospective study.
We retrospectively evaluated 1507 consecutive patients undergoing ESD at two tertiary referral centres for ESD (Italy and Japan) from January 2008 to March 2020.
Demographic, clinical, procedural, and follow-up data was collected, analysed, and compared between patients with ileocecal valve lesions (ICVL) and patients with non-ICVL.
Overall, 1507 patients were enrolled (872 M, 57.8%), of these 53 patients had lesions involving the ICV. Mean age was 70.2 years (range, 53-83 years). En-bloc resection was achieved in 52 (98%) patients. The median specimen size of ICVL was 36.4 mm (range, 8-80 mm), significantly smaller than non-ICVL (p = 0.005). Procedure time was significantly longer in the ICVL group, (71.3 vs. 58.9 min; p = 0.03). Non Granular Type Laterally Spreading Tumors (LST-NG) were significantly more frequent in the ICVL group compared to rectum (52.8% vs. 25.7; p = 0.0001). En-bloc resection rate in the ileocecal region did not differ significantly between groups (p = 0.20). Complications such as perforation and postoperative occurred respectively in 3/53 (5.7%) and 1/53 (2%) patient, and were treated conservatively. At first surveillance colonoscopy performed at 6 months, recurrent adenoma was detected in 2/53 patients (3.9%).
ESD is safe and effective for the treatment of colorectal neoplasia involving the ileocecal valve if performed by expert endoscopist in referral centres.
内镜黏膜下剥离术(ESD)是治疗结直肠黏膜浅层肿瘤的首选方法,但对于有经验的内镜医生来说,某些解剖部位也具有挑战性。回盲瓣(ICV)被认为是 ESD 技术上具有挑战性的部位。
本研究旨在分析内镜黏膜下剥离术治疗涉及回盲瓣(ICV)的结直肠肿瘤的疗效和安全性。
回顾性研究。
我们回顾性评估了 2008 年 1 月至 2020 年 3 月在意大利和日本的两个三级转诊中心接受 ESD 的 1507 例连续患者。
收集并分析患者的人口统计学、临床、程序和随访数据,并比较回盲瓣病变(ICVL)患者和非 ICVL 患者之间的数据。
共纳入 1507 例患者(872 例男性,57.8%),其中 53 例患者有回盲瓣病变。平均年龄为 70.2 岁(范围,53-83 岁)。52 例(98%)患者实现整块切除。ICVL 的中位标本大小为 36.4mm(范围,8-80mm),明显小于非 ICVL(p=0.005)。ICVL 组的手术时间明显更长(71.3 与 58.9 分钟;p=0.03)。与直肠相比,ICVL 组非颗粒状侧向扩展肿瘤(LST-NG)明显更为常见(52.8%与 25.7%;p=0.0001)。回盲瓣区域的整块切除率在两组之间无显著差异(p=0.20)。穿孔和术后并发症分别发生在 3/53(5.7%)和 1/53(2%)例患者中,均经保守治疗。首次在 6 个月时进行的随访结肠镜检查中,在 2/53 例(3.9%)患者中检测到复发性腺瘤。
如果由转诊中心的专家进行操作,内镜黏膜下剥离术治疗涉及回盲瓣的结直肠肿瘤是安全有效的。